Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2022-08-22
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of acalabrutinib and rituximab and its effect in
treating patients with previously untreated mantle cell lymphoma. Acalabrutinib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a
monoclonal antibody that binds to a protein called CD20, which is found on B-cells, and may
kill cancer cells. Giving acalabrutinib and rituximab may help to control mantle cell
lymphoma in elderly patients.